Crossmark Global Holdings, Inc. Eagle Pharmaceuticals, Inc. Transaction History

Crossmark Global Holdings, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 14, 2021	SELL	$41.72 - $51.34 $226,456 - $278,673	-5,428 Closed	0 $0
Q3 2020 Oct 08, 2020	BUY	$37.02 - $51.28 $6,663 - $9,230	180 Added 3.43%	5,428 $231,000
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $20,755 - $26,409	480 Added 10.07%	5,248 $252,000
Q1 2020 Apr 28, 2020	BUY	$34.37 - $60.07 $687 - $1,201	20 Added 0.42%	4,768 $219,000
Q4 2019 Feb 06, 2020	BUY	$54.32 - $64.31 $12,493 - $14,791	230 Added 5.09%	4,748 $285,000
Q3 2019 Oct 09, 2019	BUY	$53.25 - $59.98 $2,130 - $2,399	40 Added 0.89%	4,518 $256,000
Q2 2019 Jul 09, 2019	SELL	$46.61 - $58.45 $27,966 - $35,070	-600 Reduced 11.82%	4,478 $249,000
Q1 2019 May 02, 2019	BUY	$38.66 - $51.82 $2,319 - $3,109	60 Added 1.2%	5,078 $256,000
Q4 2018 Jan 31, 2019	BUY	$36.72 - $67.73 $52,509 - $96,853	1,430 Added 39.86%	5,018 $202,000
Q3 2018 Nov 08, 2018	BUY	$66.65 - $83.86 $17,995 - $22,642	270 Added 8.14%	3,588 $249,000
Q2 2018 Jul 31, 2018	BUY	$51.25 - $76.62 $170,047 - $254,225	3,318 New	3,318 $251,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.